Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.

Cold Spring Harbor molecular case studies - 1 Dec 2019

Colombo Ilaria, Garg Swati, Danesh Arnavaz, Bruce Jeffrey, Shaw Patricia, Tan Qian, Quevedo Rene, Braunstein Marsela, Oza Amit M, Pugh Trevor, Lheureux Stephanie

Abstract excerpt

Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's choice chemotherapy. We report for the first time temporal changes in the tumor genome assessed in sequential tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins c-myc

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Receptor, ErbB-3

Source

Open in PubMed Open full text

Identifiers

PMID: 31836588
DOI: 10.1101/mcs.a004341
PMCID: PMC6913142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.PMID 31836588Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilitySemantic proximity Read ↗

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.Semantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Semantic proximity Read ↗

The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinomaSemantic proximity Read ↗

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity Read ↗

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Semantic proximity Read ↗

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read ↗

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK InhibitionSemantic proximity Read ↗

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.